A four-gene signature associated with clinical features can better predict prognosis in prostate cancer

Cancer Med. 2020 Nov;9(21):8202-8215. doi: 10.1002/cam4.3453. Epub 2020 Sep 13.

Abstract

Prostate cancer (PCa) is one of the most deadly urinary tumors in men globally, and the 5-year over survival is poor due to metastasis of tumor. It is significant to explore potential biomarkers for early diagnosis and personalized therapy of PCa. In the present study, we performed an integrated analysis based on multiple microarrays in the Gene Expression Omnibus (GEO) dataset and obtained differentially expressed genes (DEGs) between 510 PCa and 259 benign issues. The weighted correlation network analysis indicated that prognostic profile was the most relevant to DEGs. Then, univariate and multivariate COX regression analyses were conducted and four prognostic genes were obtained to establish a four-gene prognostic model. And the predictive effect and expression profiles of the four genes were well validated in another GEO dataset, The Cancer Genome Atlas and the Human Protein Atlas datasets. Furthermore, combination of four-gene model and clinical features was analyzed systematically to guide the prognosis of patients with PCa to a largest extent. In summary, our findings indicate that four genes had important prognostic significance in PCa and combination of four-gene model and clinical features could achieve a better prediction to guide the prognosis of patients with PCa.

Keywords: clinical features; four-gene signature; prognosis; prostate cancer.

Publication types

  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • 3-Oxo-5-alpha-Steroid 4-Dehydrogenase / genetics
  • Androgen-Binding Protein / genetics
  • Biomarkers, Tumor / genetics*
  • Case-Control Studies
  • Databases, Genetic
  • Enhancer of Zeste Homolog 2 Protein / genetics
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Membrane Proteins / genetics
  • Neoplasm Grading
  • Neoplasm Staging
  • Prognosis
  • Proportional Hazards Models
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / pathology*
  • ROC Curve
  • Risk Factors
  • Survival Rate
  • Transcriptome

Substances

  • Androgen-Binding Protein
  • Biomarkers, Tumor
  • Membrane Proteins
  • PARM-1 protein, human
  • 3-Oxo-5-alpha-Steroid 4-Dehydrogenase
  • SRD5A2 protein, human
  • EZH2 protein, human
  • Enhancer of Zeste Homolog 2 Protein
  • Prostate-Specific Antigen